Cardiology · Medical Literature
LDL Cholesterol Targeting in Cardiovascular Disease
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 513-516, July 30, 2026.
Clinical relevance
In patients with established atherosclerotic cardiovascular disease (ASCVD), does targeting an LDL cholesterol level of less than 55 mg/dL result in fewer major cardiovascular events compared with targeting a level of less than 70 mg/dL over 3 years? __SNAPSHOT__ {"studyDesign":"Multicenter, open-label, randomized controlled superiority trial (Ez-PAVE; NCT04626973); the NEJM July 30, 2026 publication (Vol. 395, Issue 5, pp. 513–516) represents published correspondence letters responding to the primary trial report","setting":"17 hospital sites across South Korea; investigator-initiated","sampleSize":"n=3,048 (intensive-targeting [LDL <55 mg/dL]: n=1,526; conventional-targeting [LDL <70 mg/dL]: n=1,522)","population":"Adults aged 19–80 years with documented ASCVD, including prior acute coronary syndrome, stable angina confirmed by imaging or functional testing, prior coronary or other arterial revascularization, prior stroke or TIA, or peripheral artery disease. Mean age 64.4 years; 20.9% women; median baseline LDL 76 mg/dL. Exclusively East Asian (South Korean) population. Approximately 23% were on high-intensity statins and 28–30% on ezetimibe at baseline.","intervention":"Treat-to-target strategy aiming for LDL cholesterol <55 mg/dL (intensive targeting), using stepwise lipid-lowering therapy escalation: statin up-titration, then ezetimibe addition, then PCSK9 inhibitor use at physician discretion","comparator":"Treat-to-target strategy aiming for LDL cholesterol <70 mg/dL (conventional targeting) using the same stepwise approach","primaryOutcome":"Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina at 3 years","followUp":"Median 3.0 years","fundingSource":"Investigator-initiated grant from the Cardiovascular Research Center (Seoul, South Korea) under a contract with Yuhan Corporation (a Korean pharmaceutical manufacturer of ezetimibe-containing combination products); funders reported no role in design, analysis, or writing"}
Key findings
The median achieved LDL cholesterol during the trial was 56 mg/dL in the intensive-targeting group versus 66 mg/dL in the conventional-targeting group—a realized between-group difference of approximately 10 mg/dL. The primary composite endpoint occurred in 100 patients (Kaplan–Meier cumulative incidence 6.6%) in the intensive group versus 147 patients (9.7%) in the conventional group (HR 0.67; 95% CI 0.52–0.86; P=0.002). This represents an absolute risk reduction of 3.1% (calculated) and a relative risk reduction of 33%. The NNT over 3 years to prevent one primary endpoint event was 32 (calculated). Individual component analysis showed that the primary result was driven predominantly by reductions in nonfatal MI (0.8% vs. 1.7%; HR 0.46; 95% CI 0.23–0.91) and any revascularization (4.8% vs. 7.5%; HR 0.63; 95% CI 0.47–0.84). The harder three-component composite of cardiovascular death, nonfatal MI, and nonfatal stroke was also lower in the intensive group (2.3% vs. 3.6%; additional HR and CI not reported in available correspondence). Rates of cardiovascular death and all-cause death were reported as similar between groups (specific values not reported in available abstract/correspondence). Prespecified safety endpoints—including new-onset diabetes and statin-associated muscle symptoms—were similar between groups; notably, the intensive group showed a lower incidence of clinically significant creatinine elevation. In a prespecified subgroup analysis, no significant benefit was observed in women (7.0% vs. 5.7%; HR 1.22; 95% CI 0.66–2.28), whereas a clear benefit was present in men (6.5% vs. 10.8%; HR 0.59; 95% CI 0.45–0.79). Importantly, 39% of patients in the intensive arm never achieved the assigned LDL target of <55 mg/dL during the study period.
Practice implications
IMPORTANT LIMITATION: Only the abstract of the primary Ez-PAVE trial and published correspondence letters (NEJM Vol. 395, No. 5, pp. 513–516, July 30, 2026) were available for this summary; the full trial manuscript was not reviewed. The Ez-PAVE trial is the first randomized head-to-head comparison of two guideline-recommended LDL targets in ASCVD patients and provides the most direct available RCT evidence that a treat-to-target strategy of LDL <55 mg/dL is superior to <70 mg/dL for reducing a composite cardiovascular endpoint over 3 years. The trial did establish a statistically significant and clinically meaningful reduction in the primary composite outcome with an NNT of 32 over 3 years. However, several important qualifications apply: (1) The primary result was largely driven by revascularization—a subjective, clinician-influenced endpoint—in an open-label trial where treating physicians were aware of treatment assignment, introducing meaningful risk of performance and ascertainment bias for procedure-related endpoints; (2) There was no statistically significant reduction in cardiovascular death or all-cause mortality; (3) The relative risk reduction of 33% from only a 10 mg/dL achieved LDL difference is larger than would be predicted by established cholesterol-trialists' meta-analyses, raising questions about whether the full benefit can be attributed to the LDL difference alone; (4) The population was exclusively East Asian and predominantly male (79.1% men), substantially limiting generalizability to Western, female, and racially/ethnically diverse populations; (5) Access to newer non-statin therapies (inclisiran, bempedoic acid) was restricted by South Korean reimbursement policies, limiting achieved LDL separation; (6) The 3-year follow-up may underestimate long-term benefits given the cumulative nature of LDL-associated vascular risk. The findings are most directly applicable to East Asian men with established ASCVD. Women with ASCVD, non-Asian populations, and patients who cannot tolerate intensified lipid-lowering therapy were not adequately represented. These results are broadly concordant with and provide direct RCT support for the <55 mg/dL target endorsed in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline. __LIMITATIONS__ 1. Open-label design: Neither patients nor treating clinicians were blinded to treatment assignment; blinded outcome adjudication was used but cannot fully mitigate performance bias for soft endpoints such as revascularization decisions. 2. Composite endpoint driven by revascularization: The largest contributor to the primary result was revascularization for what appears to be stable lesions—a decision requiring clinician judgment and thus vulnerable to differential management in an unblinded trial. 3. No mortality benefit demonstrated: Rates of cardiovascular death and all-cause death were similar between groups; the trial was likely underpowered or too short to detect a mortality signal. 4. Single-country, monoethnic cohort: All 3,048 participants were enrolled at 17 South Korean sites; the exclusively East Asian sample limits generalizability to other populations. 5. Underrepresentation of women: Only 20.9% of participants were female; the subgroup analysis showed no significant benefit in women, and the trial was underpowered to draw conclusions for this group. 6. Imperfect target achievement: 39% of patients in the intensive arm never achieved LDL <55 mg/dL, partly due to limited access to PCSK9 inhibitors, inclisiran, and bempedoic acid under local reimbursement constraints—an intention-to-treat analysis in a treat-to-target design where the treatment gap was substantial. 7. Short follow-up: The 3-year observation window may underestimate the cumulative long-term benefit of lower achieved LDL. 8. Industry co-funding: Yuhan Corporation, which manufactures ezetimibe-combination products, co-funded the trial, representing a potential conflict of interest, even if funders reported no role in conduct. 9. Effect size larger than predicted: The observed 33% relative risk reduction from a ~10 mg/dL achieved LDL difference exceeds what would be expected from cholesterol-trialists' epidemiological models, warranting scrutiny for confounding or bias. 10. Generalizability of achieved LDL gap: Real-world patients in Western settings, with broader access to PCSK9 inhibitors and newer agents, may achieve a larger LDL differential—potentially increasing benefit, but this is speculative. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ The Ez-PAVE trial provides the first direct RCT evidence that a treat-to-target LDL strategy of <55 mg/dL reduces a composite cardiovascular endpoint (HR 0.67; NNT=32 over 3 years) compared with <70 mg/dL in patients with established ASCVD, thereby offering randomized support for current 2026 ACC/AHA guideline recommendations. Clinicians should note that the primary composite was driven substantially by revascularization in an open-label trial, no mortality benefit was demonstrated, and findings derive exclusively from an East Asian, predominantly male population. For most patients with established ASCVD—particularly those at very high risk—intensification of lipid-lowering therapy to achieve LDL <55 mg/dL is supported by this evidence, though individualized shared decision-making is warranted given the trial's generalizability constraints.